! 17:50*17:55!!!!Introduction!
!
! 17:55*18:15!!!Allogeneic!stem!cell!transplantation!for!PTCL!patients:! Ghandi!Laurent!Damaj!(Caen)(
/ /////////////////////////Why!and!when?/
!
! 18:15*18:35!!!Perspectives!of!integrating!immunotherapy! ! ! Gerald!Wulf!(Göttingen)
in!PTCL!treatment!algorithms
!
! 18:35*18:55!!!Discussion!Q!&!A!
!
18:55*19:55( 5(Simultaneous(Meet(the(Expert(sessions:((
1. Circulating!free!DNA!! Davide!Rossi!(Bellinzona),!Simone!Ferrero!(Turin)!
2. Pet!scan!in!lymphoma!! Michel!Meignan!(Créteil)!and!Stefano!Luminari!(Modena)!
3. Artificial!intelligence!for!the!diagnosis!on!lymphoma!!! Camille!Laurent!(Toulouse)!and!Ahmet!Dogan!(New!York)!
4. Follicular!lymphoma!! Christian!Buske!(Ulm)!and!Nathan!Fowler!(Houston)!
5. Car!T*cell!! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Stephen!Schuster!(Philadelphia)!and!Catherine!Thieblemont!(Paris)!
((
(((((((( Saturday,(November(7(
11:00*12:55((((SESSION(III(–(Follicular(Lymphoma(
( Chairs:(Christian(Buske((Ulm)(and(Franck(Morschhauser((Lille)(
!
11:00*11:05! Introduction!
!
11:05*11:25! Diagnostics! Wolfram!Klapper!(Kiel)!
!
11:25*11:45! First!line! Stefano!Luminari!(Modena)!
!
11:45*12:05! Salvage!treatment! Franck!Morschhauser!(Lille)!
/ !
12:05*12:25! Challenges!in!FL!–!POD24! Emmanuel!Bachy!(Lyon)/ !
(
12:25*12:30! EZH2/gainMofMfunction/mutations/are/not/associated/with/ Csaba/Bödör/(Budapest)/
/ more/favorable/prognosis/in/relapsed/refractory/follicular//
/ lymphoma:/a/preliminary/analysis/on/908/patients/
(
12:30*12:55! Discussion/Q/&/A//
/
!
12:55*14:30! Lunch!
!
13:30*14:30! !SATELLITE(SYMPOSIUM(
!/
(Immunotherapy:(the(new(cornerstone(of(lymphoma(care((
(Chair:(Stefano!Luminari!(Reggio!Emilia)!
(Speakers:(Stefano!Luminari!(Reggio!Emilia),!Andrew!Davies!(Southampton)!and!Marc%André%(Namur)!
/
This/educational/symposium/is/organized/and/funded/by/Celgene/|/A/Bristol/Myers/Squibb/Company/
!((
14:35*15:35( Mentored(Poster(Walk(
( Leader:(Elias(Campo((Barcelona)((
3
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES